Neuraminidase inhibitors--the story behind the Cochrane review
BMJPublished 8 December 2009
Peter Doshi
Citations87
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Although billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidence base for this global public health drug was fragmented and inconsistent.
Abstract
Although billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidence base for this global public health drug was fragmented and inconsistent. Peter Doshi tells the story
Keywords
Medicine
PsycEXTRA DatasetPrevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
5,046 Citations2001C B Bridges, Keiji Fukuda +2 more
The 2004 recommendations include new or updated information regarding 1) influenza vaccine for children aged 6-23 months; 2) vaccination of health-care workers with live, attenuated influenza vaccine (LAIV); 3) personnel who may administer LAIV; and the assessment of vaccine supply and timing of influenza vaccination.
PsycEXTRA DatasetPrevention and Control of Influenza; Recommendations of the Advisory Committee on Immunization Practices (ACIP)
1,709 Citations2002
Prepared by Anthony E. Fiore, MD, Gina Mootrey, DO, and Nancy J. Cox.
Health Technology AssessmentHow important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study
1,169 Citations2003Matthias Egger, Peter Jüni +3 more
JAMAEfficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza
997 Citations2000John J. Treanor, Frederick G. Hayden +9 more
The data suggest that oral oseltamivir treatment reduces the duration and severity of acute influenza in healthy adults and may decrease the incidence of secondary complications.
The LancetEfficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
779 Citations2000KG Nicholson, F. Y. Aoki +7 more
Oseltamivir was associated with lower [corrected] symptom scores, less viral shedding, and improved health, activity, and sleep quality, and was well tolerated in the treatment of natural influenza infection in adults.
PsycEXTRA DatasetInfluenza Vaccination of Health-Care Personnel: Recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP)
531 Citations2006Michele L. Pearson, Carolyn B. Bridges +1 more
Archives of Internal MedicineImpact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations
501 Citations2003Laurent Kaiser, Cynthia Wat +4 more
Oseltamivir treatment of influenza illness reduces LRTCs, antibiotic use, and hospitalization in both healthy and "at-risk" adults.
BMJNeuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis
360 Citations2009T. Jefferson, Mark Jones +2 more
The remaining evidence suggests oseltamivir did not reduce influenza related lower respiratory tract complications and neuraminidase inhibitors have modest effectiveness against the symptoms of influenza in otherwise healthy adults.
JAMADoes This Patient Have Influenza?
351 Citations2005Stephanie Call
Clinicians should use timely epidemiologic data to ascertain if influenza is circulating in their communities, then either treat patients with influenza-like illness empirically or obtain a rapid influenza test to assist with management decisions.
Health Technology AssessmentMethods to identify postnatal depression in primary care: an integrated evidence synthesis and value of information analysis
333 Citations2009Catherine Hewitt, Simon Gilbody +9 more
Suggestive evidence from the clinical effectiveness review indicated that use of the EPDS, compared with usual care, may lead to reductions in the number of women with depression scores above a threshold, and evidence surrounding clinical and cost-effectiveness of methods to identify PND is lacking.
Health Technology AssessmentSystematic review and economic decision modelling for the prevention and treatment of influenza A and B
246 Citations2003David Turner, Allan Wailoo +4 more
The cost-effectiveness varies markedly between the intervention strategies and target populations and the estimate of cost effectiveness is also sensitive to variations in certain key parameters of the model, for example the proportion of all influenza-like illnesses that are influenza.
Cochrane Database of Systematic ReviewsNeuraminidase inhibitors for preventing and treating influenza in healthy adults
228 Citations2006Tom Jefferson, Mark Jones +5 more
Drug SafetyAssessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir
164 Citations2008Stephen Toovey, Craig R. Rayner +15 more
This review summarizes the results of a comprehensive assessment of the company’s own preclinical and clinical studies, post-marketing spontaneous adverse event reporting, epidemiological investigations utilizing health claims and medical records databases and an extensive review of the literature on neuropsychiatric abnormalities reported in patients with influenza.
Health Technology AssessmentAmantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation
137 Citations2009Paul Tappenden, R Jackson +5 more
All three interventions showed some efficacy for seasonal and post-exposure prophylaxis and weaknesses and gaps in the clinical evidence base are directly relevant to the interpretation of the health economic model and rendered the use of advanced statistical analyses inappropriate.
Technology and CultureScience, Politics, and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation
137 Citations1998Susan Lindee, John Abraham
John Abraham proposes that corporate bias could be reduced by more extensive freedom of information, greater autonomy of government scientists from pharmaceutical industry, the development of independent drug testing by the regulatory authority, increased patient representation on regulatory committees, and more frequent and thorough oversight of regulatory performance by the legislature.
The Lancet Infectious DiseasesPrescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis
116 Citations2009Jane Burch, Mark Corbett +7 more
Recommendation of antiviral drugs for the treatment of people presenting with symptoms is unlikely to be the most appropriate course of action in healthy adults and people at-risk of influenza-related complications.
BMJScience, Politics, and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation
95 Citations1995Joe Collier
John Abraham UCL Press, pounds sterling12.95, pp 308 ISBN 1 85728 200 0 John Abraham's book on the relationship between the regulators and the pharmaceutical industry is a classic.
The Medical Journal of AustraliaA pandemic response to a disease of predominantly seasonal intensity
37 Citations2010Heath Kelly
From the recognition of the swine flu pandemic in late April 2009, health professionals, politicians and the public needed to know how serious pandemic (H1N1) 2009 influenza (swine flu) was in relation to other seasonal strains of influenza.
The LancetAntivirals for influenza in healthy adults
17 Citations2006James Smith, Regina Dutkowski +1 more